Breaking News, Promotions & Moves

Iterative Health Adds Nadege Gunn as CMO, Hepatology and Obesity

Gunn will provide medical and scientific leadership across metabolic liver disease research and specialized site operations.

Author Image

By: Patrick Lavery

Content Marketing Editor

Iterative Health has hired Nadege Gunn, MD, as Chief Medical Officer (CMO), Hepatology and Obesity. Gunn currently practices at Texas-based Coryell Health, serving there as hepatology clinic director. She is the founder, and former president and CEO, of the hepatology-focused Impact Research Institute in Waco, Texas.

Role of New CMO

Gunn’s appointment to the Iterative Health team serves to provide strategic medical and scientific leadership in metabolic liver disease research. Gunn will also oversee specialized site operations to support Iterative Health’s expanding hepatology and obesity portfolio.

By strategically collaborating with biopharmaceutical sponsors and contract research organization (CRO) partners, Gunn will impact future plans for Iterative Health. These include creating a performance-driven network of research sites expanding access to multispecialty therapies, and accelerating novel therapies to market.

Other Iterative Health Moves

Iterative Health is also promoting Dana Feuchtbaum from Chief Product Officer to Chief Operating Officer. Feuchtbaum said that Gunn joining the team will benefit providers and sponsors alike.

“Gunn strengthens the clinical leadership and operational confidence behind every hepatology and obesity study we support,” Feuchtbaum said. “Her appointment accelerates our ability to support increasingly complex hepatology and obesity trials at scale.”

Prior Gunn Experience

Gunn expressed excitement for Iterative Health’s focus on “extending cutting-edge clinical research into the communities that care for these patients.”

“Iterative Health has created an impressive foundation to advance hepatology and obesity research at scale,” Gunn said.

Impact Research Institute, which Gunn founded, is recognized as a leading U.S. hepatology research center. Gunn is also a committee member of Women in Hepatology: Initiatives, Sponsorship, and Empowerment within the Chronic Liver Disease Foundation.

Her academic resume includes teaching posts at Texas A&M, the University of Texas at Austin, and Baylor University.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters